Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Phase 2

Completed

• Conditions: Condylomata Acuminata; Cervical Cancer
• Interventions: Biological: HPV Vaccine,270μg/1.0ml; Biological: Placebo

• Registration Number: NCT03935204
• Lead Sponsor: Xiamen University

Brief Summary

This phase II clinical study was designed to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)(hereafter called HPV vaccine), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy adults aged 18-45 years old.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-04-30
• Study First Submitted QC: 2019-04-30
• Study First Posted: 2019-05-02
• Study Start: 2019-05-13
• Primary Completion: 2019-10-18
• Status Verified: 2021-04
• Study Completion: 2021-04-01
• Last Update Submitted: 2021-04-07
• Last Update Posted: 2021-04-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 627

Inclusion Criteria

1. Health women aged between 18 and 45 years.
2. Judged as healthy and eligible for vaccination by the investigators through a self-reported medical history and some physical examinations.
3. Able to comply with the requests of the study.
4. Written informed consent obtained from the participants.
5. Axillary temperature not higher than 37.0°C
6. Non-pregnant women verified by a urine pregnancy test.

Exclusion Criteria

1. Pregnant or breastfeeding or plan to be pregnant within 7 months.
2. Use of any investigational product or non-registered product (drug or vaccine) within 30 days preceding the first dose of the study vaccine or plan to use during the study period.
3. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, except local treatment.
4. Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine or plan to use within 7 months.
5. Administration of any attenuated live vaccines within 21 days preceding the first dose of the study vaccine or any subunit or inactivated vaccines within 14 days before vaccination.
6. Had a fever (axillary temperature over 38°C) within 3 days or acute illness requiring systemic antibiotics or antiviral treatment within 5 days before vaccination.
7. Having the plan to participate another clinical trial during the study period.
8. Received another HPV vaccine.
9. Immunodeficiency , primary disease of important organs, malignant tumor, or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response).
10. History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy, urticaria, dyspnea, angioneurotic edema or abdominal pain.
11. Asthma that required emergent treatment, hospitalization, oral or intravenous corticosteroid for unstable condition within the past 2 years.
12. Having serious disease of internal medicine, such as hypertension, cardiac disease, diabetes, hyperthyroidism et al.
13. Diagnosed coagulant function abnormality or blood coagulation disorder.
14. Epilepsy, except fever epilepsy at under 2 years of age, alcohol-induced epilepsy in 3 years before abstinence, or idiopathic epilepsy requiring no treatment in the past 3 years.
15. Past or current two-stage affective psychosis, not well controlled in the past 2 years or requiring drugs, or hve a tendency to commit suicide in the past 5 years.
16. Other medical, psychological, social or occupational factors that, according to the investigators' judgment, might affect the individual's ability to obey the protocol or sign the informed consent.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
HPV Vaccine,270μg/1.0ml	HPV Vaccine,270μg/1.0ml	Participants in this arm would receive 270μg/1.0ml HPV vaccines.
Placebo	Placebo	Participants in this arm would receive 1.0ml aluminium adjuvant.

Primary Outcome Measures

Name	Time	Method
Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 7 (type specific neutralizing antibody)	month 7	To detect the anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific neutralizing antibody level on day 0 (before the 1st dose) and one month after dose 3

Secondary Outcome Measures

Name	Time	Method
Unsolicited adverse events	Within 30 days (Day 0-29) after any vaccination	Unsolicited adverse reactions occurred within 30 days after each vaccination;
Solicited local adverse reactions	During the 7-day (Day 0-6) period following each vaccination	Solicited local adverse reactions occurred within 7 days after each vaccination;
Serious adverse events	throughout the study period, an average of 7 months	Serious adverse events occurred throughout the study;
Solicited systematic adverse reactions	During the 7-day (Day 0-6) period following each vaccination	Solicited systematic adverse reactions occurred within 7 days after each vaccination;

Trial Locations

Locations (1)

Jiangsu Provincial Centre for Disease Control and Prevention; 🇨🇳 Nanjing, Jiangsu, China